Haleon plc Reports Share Transaction
Ticker: HLNCF · Form: 6-K · Filed: Sep 19, 2025 · CIK: 1900304
Sentiment: neutral
Topics: share-transaction, 6-K, disclosure
TL;DR
Haleon bought back its own shares on 9/19/25. Details in 6-K.
AI Summary
Haleon plc announced a transaction in its own shares on September 19, 2025. The filing, a Form 6-K, details this transaction as required for foreign private issuers. No specific financial figures or share counts were provided in the excerpt.
Why It Matters
This filing indicates corporate activity related to Haleon's own stock, which can signal management's view on the company's valuation or capital allocation strategies.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a share transaction and does not contain information suggesting significant new risks.
Key Players & Entities
- Haleon plc (company) — Registrant
- September 19, 2025 (date) — Date of share transaction
- 001-41411 (other) — Commission File Number
FAQ
What type of transaction did Haleon plc conduct in its own shares on September 19, 2025?
Haleon plc conducted a 'Transaction in Own Shares' as detailed in Exhibit 99.1 of the Form 6-K filing.
What is the filing type and date?
The filing is a Form 6-K, reported for the month of September 2025, with the specific transaction dated September 19, 2025.
What is Haleon plc's principal executive office address?
Haleon plc's principal executive offices are located at Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY.
Is Haleon plc required to file annual reports under Form 20-F or Form 40-F?
Haleon plc is required to file annual reports under Form 20-F, as indicated by the checkmark next to it in the filing.
What was Haleon plc's former name?
Haleon plc's former name was DRVW 2022 Ltd, with a date of name change on December 17, 2021.
Filing Stats: 582 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-09-19 06:16:33
Filing Documents
- a9599z.htm (6-K) — 34KB
- a9599z000.jpg (GRAPHIC) — 3KB
- 0001654954-25-010925.txt ( ) — 40KB
From the Filing
IN OWN SHARES a9599z UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2025   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1 19 September 2025 - “Transaction in Own Shares”     99.1     Haleon plc:   Transaction in own shares   19 September 2025:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of 4,314,000 ordinary shares of £0.01 each in the Company (the "Shares")   under the second tranche of its share buyback programme announced on 31 July 2025.     London Stock Exchange CBOE (UK)/BXE CBOE (UK)/CXE Date of purchase: 18 September 2025 18 September 2025 18 September 2025 Number of Shares purchased: 3,374,000 940,000 - Highest price paid per Share (p): 344.4500 342.0000 - Lowest price paid per Share (p): 340.2000 340.2000 - Volume weighted average price paid per Share (p): 341.8544 341.2133 -   The Company intends to hold the purchased shares as treasury shares.   Following the settlement of the above, the Company's registered share capital   is 8,952,353,648 ordinary shares of £0.01 each, of which 18,887,545 are held as treasury shares.   Therefore, the number of ordinary shares with voting rights is 8,933,466,103 and   this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/9590Z_1-2025-9-18.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Jo Russell   +44 7787 392441 Zoë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Victoria Durman +44 7894 505730 Email:   investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as  Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu  and  Voltaren  - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .            SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 19, 2025 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary